ScoreWhy is Xilio Therapeutics, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 139.31% and Operating profit at 9.25% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -64.55
2
With a growth in Net Sales of 742.51%, the company declared Outstanding results in Sep 25
- The company has declared positive results for the last 5 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -17.16 MM
- RAW MATERIAL COST(Y) Fallen by -19.55% (YoY)
- DEBTORS TURNOVER RATIO(HY) Highest at 3.63 times
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -27.56%, its profits have risen by 30.4%
4
High Institutional Holdings at 62.32%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Below par performance in long term as well as near term
- Along with generating -27.56% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Xilio Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Xilio Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Xilio Therapeutics, Inc.
-27.56%
0.46
1407.27%
S&P 500
14.9%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
139.31%
EBIT Growth (5y)
9.25%
EBIT to Interest (avg)
-64.55
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-8.21
Sales to Capital Employed (avg)
-0.25
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
62.32%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-4.96
EV to EBIT
1.42
EV to EBITDA
1.48
EV to Capital Employed
0.56
EV to Sales
-1.96
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
39.60%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend30What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -17.16 MM
RAW MATERIAL COST(Y)
Fallen by -19.55% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 3.63 times
NET SALES(Q)
Highest at USD 19.07 MM
OPERATING PROFIT(Q)
Highest at USD -1.59 MM
OPERATING PROFIT MARGIN(Q)
Highest at -8.33 %
PRE-TAX PROFIT(Q)
Highest at USD -0.91 MM
NET PROFIT(Q)
Highest at USD -0.91 MM
EPS(Q)
Highest at USD -0.11
-3What is not working for the Company
ROCE(HY)
Lowest at -908.28%
DEBT-EQUITY RATIO
(HY)
Highest at 1,192.11 %
Here's what is working for Xilio Therapeutics, Inc.
Net Sales
At USD 19.07 MM has Grown at 742.51%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -17.16 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 19.07 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD -1.59 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at -8.33 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD -0.91 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD -0.91 MM has Grown at 93.55%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -0.91 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Net Profit
At USD -0.91 MM has Grown at 93.55%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.11
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debtors Turnover Ratio
Highest at 3.63 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -19.55% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Xilio Therapeutics, Inc.
Debt-Equity Ratio
Highest at 1,192.11 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
